ABUS earnings call for the period ending December 31, 2018.
News & Analysis: Arbutus Biopharma
The clinical-stage biotech reported good news and bad news -- with the bad outweighing the good.
A new drug candidate that licences Arbutus Biopharma's proprietary technology passed an important milestone.
Returns couldn't have been much worse for these drugmakers this year.
The Ebola outbreak has the nation, and world, on edge. Here we'll take a look at some of the more common questions involving what the Ebola virus is, how it spreads, what's being done to stop it.
Here's what you need to know about Ebola and the three companies arguably closest to developing a cure.
Experimental ebola vaccine makers' stocks skyrocketed following the first confirmed case of Ebola on U.S. soil. Find out what investors should really be doing following this news.